Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662356 | 0.94 | CXCR4 (0.42) | CXCR4PARP1LTA4H | |
| SCHEMBL5472330 | 0.88 | CXCR4 (0.53) | CXCR4HRH3 | |
| SCHEMBL5242408 | 0.86 | — | — | |
| SCHEMBL1408398 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL6298213 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL3021251 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL2417776 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL6224046 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL6224053 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 | |
| SCHEMBL31135581 | 0.78 | CXCR4 (0.44) | CXCR4PARP1LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
| EP-1569638-B1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-7084169-B2 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1569638-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | disclosed |
| US-6358949-B1 | CARDIOVASCULAR AND SEXUAL DISORDERS; DIABETES, KIDNEY DISEASE, LIVER CIRRHOSIS; ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIASTHMATICS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1165518-A2 | BENZIMIDAZOLE AND IMIDAZOLOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MODULATORS OF BRADYKININ B2 (= BK-2) RECEPTORS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059886-A2 | BENZIMIDAZOLE ABD IMIDAZOLOPHYRIDINE DERIVATIES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MODULATORS OF BRADYKININ B2 (=BK-2) RECEPTORS | NEUROGEN CORPORATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | CXCR4 620/4885PARP1 895/4885LTA4H 4705/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | CXCR4 408/4885PARP1 1062/4885LTA4H 4788/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | CXCR4 620/4885PARP1 895/4885LTA4H 4705/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | CXCR4 408/4885PARP1 1062/4885LTA4H 4788/4885 |
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, HRH2 | CXCR4 272/4885PARP1 1975/4885LTA4H 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.